Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1634661
Author(s) Joerger, Markus; Thürlimann, Beat; Savidan, Anita; Frick, Harald; Bouchardy, Christine; Konzelmann, Isabelle; Probst-Hensch, Nicole; Ess, Silvia
Author(s) at UniBasel Probst Hensch, Nicole
Year 2012
Title A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer
Journal Clinical breast cancer
Volume 12
Number 2
Pages / Article-Number 102-9
Keywords Breast cancer, Chemotherapy, Epidemiology, Guidelines, Socioeconomic factors
Abstract BACKGROUND: There is considerable heterogeneity in the use of chemotherapy for patients with early breast cancer (BC), despite international recommendations issued from the National Comprehensive Cancer Network (NCCN), National Institutes of Health (NIH), and the St. Gallen biannual conference. This population-based study assessed the patterns of chemotherapy use in early BC. PATIENTS AND METHODS: The study included all or representative samples of patients with stage I-III BC from 7 Swiss cancer registries between 2003 and 2005. Factors modifying chemotherapy use were determined by logistic regression, considering patients receiving chemotherapy as cases (n = 1535) and the others as controls (n = 2004). RESULTS: Nodal involvement was by far the strongest predictor for the use of chemotherapy (adjusted odds ratio [OR], 9.7; 95% confidence interval [CI], 7.2-13.0). Tumor biological characteristics such as histologic differentiation (OR, 4.4; 95% CI, 3.2-6.2), estrogen receptor (ER) status (OR, 3.8; 95% CI, 2.6-5.5), human epidermal growth factor receptor 2 (HER2) status (OR, 1.9; 95% CI, 1.3-2.7), and patient age (OR, 4.6; 95% CI, 3.5-6.2) were less important predictors for chemotherapy use. Socioeconomic and provider-related factors, such as patient education, affluence, insurance, breast surgeon's annual caseload, and case presentation at a multidisciplinary tumor conference did not predict the use of chemotherapy, with the exception of the health care provider's participation in clinical research (OR, 2.1; 95% CI, 1.6-2.8). The patient's region of residence did not predict the use of chemotherapy, but it was associated with the specific type of chemotherapy used. CONCLUSION: Nodal status, rather than surrogate markers for tumor biological features, was the predominant factor for choosing chemotherapy in patients with early BC in this large population study. Improvements should be made to increase the weight of tumor biological features in choosing chemotherapy in early BC
Publisher Cancer Information Group
ISSN/ISBN 1526-8209
edoc-URL http://edoc.unibas.ch/dok/A6094040
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.clbc.2011.10.005
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/22138066
ISI-Number WOS:000302207100004
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.357 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
26/04/2024